The Open Philanthropy Project has been feeling out different approaches for its nascent science program. One interesting RFP sent $11 million to a handful of applicants the NIH had to turn away.
While the days of doctors making house calls are long gone, one couple is trying to bring the practice back for Parkinson’s patients, who can end up homebound and unable to get the treatment they need.
While you might think that a lot of major health funders would be focused on diabetes, that's not really the case. On the upside, some of the foundations that are paying attention have very deep pockets.
Critics worry that a $200 million donation for alternative medicine from a tech billionaire and his wife will tar UC Irvine's Medical School as a haven for quacks. But the gift raises larger questions.
The Breast Cancer Research Foundation is a great example of how funding intermediaries keep gaining momentum, wielding new resources and clout, especially when it comes to medical research.
Sickle cell disease affects millions of people worldwide and is the most common inherited blood disorder in the U.S., but few funders prioritize finding a cure. Here's a major exception.
In what's becoming a familiar trend, a gift to Boston University finds a billionaire donor trying to propel his alma mater to the upper echelons of the American university research system with a stroke of a pen.
More than 95 percent of healthcare spending goes to direct medical services, but 70 percent of health outcomes can be tied to social determinants. A group of funders wants to change that dynamic.
Women of color account for 80 percent of new HIV diagnoses. But stigma and isolation can make it uniquely difficult for these women to get treatment. A pharma funder is working the problem.
Philanthropic giving for disease research pales next to what the Feds spend. But funders try to get a lot of bang for the buck by backing young scientists and riskier projects. Hilton's giving on MS is a case in point.
Heavy hitters like Gates and Wellcome Trust are demanding that grantees publicly disclose the results of all clinical trials within 12 months. Till Bruckner of Transparify explains what's at stake.
A breakthrough in gene-altering cancer therapy is a case study of how philanthropy can play a role in advancing important research, in tandem with government and industry.
Pancreatic cancer is one of the toughest cancers out there, as far as funding is concerned. But a push to mobilize new resources has been gaining steam—and financing increasingly interesting grants.
The Microsoft billionaire is giving tens of millions of dollars to support "out-of-the-box approaches at the very edges of knowledge." What does that look like in practice, exactly?
A lot is happening with the Parker Institute for Cancer Immunotherapy that the tech billionaire launched last year. But is this thing living up to all the hype that surrounded its rollout?
Until the intervention of the Helmsley Charitable Trust a decade ago, type 1 diabetes was something of a stepchild in the medical research world. The foundation has helped to change that.
Big gifts are flowing for local cancer treatment facilities that offer care that was once unavailable in places like rural Maine. But there are growing questions about effectiveness.
In an era of uncertain federal commitments, how can philanthropy refocus its energies on what remains a profound global health crisis? We talk to the leaders of Funders Concerned About AIDS.
A growing number of funders are excited about using genomics to design and implement far more precise and effective medical treatments plans, saving lives, and also money. Where are grants going?
Embracing risk taking, Cancer Research U.K. (CR-UK) is backing some pretty innovative and potentially groundbreaking cancer research projects.
Philanthropy can’t make up the financial void that would be left by severe cuts in federal funding. But the Bezos family has come forward with a big gift at a key moment, tapping its vast Amazon wealth.
Metropolitan Bank Group cofounders Peter and Paula Fasseas have a passion for supporting animals in their philanthropy and have helped spearhead the local no-kill movement in Chicagoland. We take a look.
Former Highland Capital Partners Managing Partner and Boston Celtics CEO Wyc Grousbeck focuses his health philanthropy on issues of sight and vision. We tell you the deeply personal reasons why and what the financier supports.
Bioelectronic medicine, a fairly new discipline that marries neuroscience, molecular biology, cell biology, and bioengineering, has been around awhile. Now, new money is flowing into this promising field.
A big first round of research grants has gone out the door from the Biohub, giving awards of $1.5 million over five years to dozens of lucky scientists. What's the future hold for this new initiative?
Wellcome Trust, the world's second-largest foundation, spends a fortune to find new health breakthroughs. Now, it's making a push to ensure that research translates into actual health gains.
Backing high-tech medical seems a bit risky for a nearly 50-year-old institution. But JDRF isn’t really one of those outfits happy to travel the well-beaten path.
As new deep-pocketed donors move into biomedical research, we're seeing new funding for health issues that have often been overlooked. How the Klarmans are tackling eating disorders is a case in point.
We take a closer look at the “first large-scale precision medicine trial for pancreatic cancer," as well as the money behind efforts to fight this deadly form of cancer.